Sugi Predict

Sugi Predict / Compounds / SCHEMBL1907296

SCHEMBL1907296

SCHEMBL1907296

N#Cc1c(-c2ccc(Oc3ccccc3)cc2)cn(-c2cccc(CO)c2)c1N

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 4/20 0.45
▸ ABL1 P00519 2/20 0.45
▸ EGFR P00533 2/20 0.45
▸ CDK1 P06493 2/20 0.45
▸ ABL2 P42684 2/20 0.45
▸ BTK Q06187 7/20 0.42
▸ GRM2 Q14416 2/20 0.40
▸ CA12 O43570 2/20 0.40
▸ CA1 P00915 2/20 0.40
▸ CA2 P00918 2/20 0.40
▸ CA9 Q16790 2/20 0.40
▸ AS3MT Q9HBK9 2/20 0.40
▸ LTA4H P09960 1/20 0.39
▸ MEN1 O00255 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14673720 0.95 CA12 (0.48) SRCABL1EGFRCDK1ABL2
SCHEMBL1902613 0.84 CA12 (0.56) SRCABL1EGFRCDK1ABL2
SCHEMBL7844630 0.81 AS3MT (0.55) SRCABL1EGFRCDK1ABL2
SCHEMBL7833944 0.78 AS3MT (0.49) GRM2AS3MT
SCHEMBL7836453 0.78 AS3MT (0.42) SRCABL1EGFRCDK1ABL2
SCHEMBL7835925 0.75 CA12 (0.54) SRCABL1EGFRCDK1ABL2
SCHEMBL1901072 0.74 SRC (0.82) SRCABL1EGFRCDK1ABL2
SCHEMBL7847918 0.73 SRC (0.55) SRCABL1EGFRCDK1ABL2
SCHEMBL27195209 0.73 CA12 (0.44) SRCABL1EGFRABL2CA12
SCHEMBL7835893 0.72 KDM4E (0.50) SRCCA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9505766-B2 Kinase inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-11-29 — — US disclosed
US-20150045343-A1 KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-02-12 — — US disclosed
US-20150045343-A1 KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-02-12 — — US disclosed
EP-2558099-A2 KINASE INHIBITORS The Regents Of The University Of California, San Francisco (US) 2013-02-20 — — EP disclosed
US-20130035325-A1 KINASE INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-02-07 — — US disclosed
US-20130035325-A1 KINASE INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-02-07 — — US disclosed
CN-102711765-A Kinase inhibitors UNIV CALIFORNIA 2012-10-03 — — CN disclosed
WO-2011060440-A2 KINASE INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-05-19 — — WO disclosed
WO-2011060440-A2 KINASE INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130035325-A1 KINASE INHIBITORS MAP3K20, MAP3K19, MAP3K8 SRC 84/4885ABL1 32/4885EGFR 347/4885
US-20150045343-A1 KINASE INHIBITORS MAP3K20, MAP3K19, MAP3K8 SRC 84/4885ABL1 32/4885EGFR 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.